Moffitt Cancer Center | Strategic Alliance Partners

Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.

Two of North America's leading cancer centers announced what is likely the largest collaboration of its kind to accelerate discoveries in cancer research.

A 10-year follow-up study of regional melanoma staging strategies found that patients who underwent sentinel-node biopsies had significantly greater disease-free survival rates (DFSRs) compared with patients monitored through nodal observation.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.

During the past decade, several oral tyrosine kinase inhibitors targeting the vascular endothelial growth factor have been approved for the first-line treatment of metastatic renal cell carcinoma.

Awake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

Adjuvant therapy for patients with advanced melanoma and the optimal use of molecular testing are among the most pressing issues facing oncologists who treat patients diagnosed with the disease.

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

After decades with few available therapies, a flurry of FDA drug approvals has provided oncologists with a variety of options for treating patients with advanced melanoma.

Jeffrey S. Weber, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the immunologic activities of targeted agents for the treatment of melanoma.

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.

Molecular testing and novel therapies have revolutionized the management of metastatic melanoma in recent years.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses testing for genetic mutations in patients with melanoma.

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.

IDO is a key enzyme in the normal regulation of the host's adaptive immune response. Its role in regulating the immune response was initially demonstrated when pregnant mice were given IDO inhibitors, resulting in the rejection of the unborn fetus by the maternal immune system.

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.

Arnold B. Etame, MD, PhD, from the Moffitt Cancer Center, describes stereotactic neuronavigation, which may offer more surgical visualization capabilities for the neurosurgeon.

Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Patients receiving transplants from unrelated donors to treat various hematologic malignancies may benefit more from receiving adult stem cells harvested from bone marrow rather than peripheral-blood stem cells (the current standard).

Jeffrey S. Weber, MD, PhD, specializes in cancer immunotherapy and has been involved in numerous trials of clinical drug development, vaccines, and studies on autoimmunity and melanoma.

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

Paul Jacobsen, from the H. Lee Moffitt Cancer Center and Research Institute, Discusses Survivorship Care Plans

Located in Tampa, Florida, Moffitt Cancer Center enjoys a reputation as one of the world's most sophisticated cancer centers.

A combination of immunotherapy and fractionated external-beam radiation therapy provided tumor-specific immune responses in patients with soft-tissue sarcoma.